Diane K. Jorkasky

Diane K. Jorkasky, MD FACP is a highly regarded medical scientist with a broad background across research and all phases of clinical development in multiple therapeutic areas. Dr. Jorkasky currently serves as an Expert Consultant at NDA Partners – a life sciences management consulting and contract development organization.

Most recently Dr. Jorkasky was Chief Medical Officer, Head of Development, and Executive Vice President of Complexa Inc. (Berwyn, PA) whose nitro fatty acid signaling technology is being developed for rare diseases of the kidney and cardiopulmonary systems. Additionally, Dr. Jorkasky served as Chief Medical Officer at Endo Pharmaceuticals (Chadds Ford, PA), and Aileron Therapeutics (Cambridge, MA) where she guided the development of stapled peptides in oncology.

At Pfizer Global R&D (New London, CT), she served as Vice President of Global Clinical Research Operations, responsible for all exploratory development, clinical pharmacology (phase 1-4), and translational medicine. Dr. Jorkasky led the Pfizer International Clinical Research Units which received certification by American Accreditation for Human Rights Protection Policies for their clinical research process, the first in industry or academia to achieve such recognition. Previously, she was Vice President of Clinical Research at SmithKline Beecham and Chief of Nephrology at Presbyterian-Penn Medical Center in Philadelphia.

Dr. Jorkasky is a member of the Connecticut Academy of Science and Technology and has been recognized by the Connecticut Women’s Hall of Fame for her scientific leadership and mentoring of young women. Dr. Jorkasky is board certified in internal medicine, nephrology, and clinical pharmacology, having received her medical degree from the University of Pennsylvania. She has been on the faculties of UCSF, Yale, Penn, and Uniformed Service of Health Sciences Medical Schools has published over 100 peer review articles, and is a Woodrow Wilson Visiting Fellow.

Dr. Jorkasky is qualified to serve on the board of directors because of her extensive experience in the pharmaceutical and biotechnology industries.